Galecto, Inc. Files 8-K for Bylaw Amendments & Financials
Ticker: DMRA · Form: 8-K · Filed: Sep 5, 2024 · CIK: 1800315
| Field | Detail |
|---|---|
| Company | Galecto, INC. (DMRA) |
| Form Type | 8-K |
| Filed Date | Sep 5, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, financial-reporting, regulatory-filing
TL;DR
Galecto filed an 8-K for bylaw changes and financials. Nothing major.
AI Summary
Galecto, Inc. filed an 8-K on August 29, 2024, reporting amendments to its articles of incorporation or bylaws and financial statements. The company, incorporated in Delaware with its principal executive offices in Boston, MA, operates in the pharmaceutical preparations sector.
Why It Matters
This filing indicates routine corporate governance updates and financial reporting by Galecto, Inc., providing transparency to investors about the company's operational and legal status.
Risk Assessment
Risk Level: low — The filing pertains to standard corporate reporting and does not indicate any significant operational changes or financial distress.
Key Numbers
- 001-39655 — SEC File Number (Identifies the company's filing with the SEC)
- 37-1957007 — IRS Employer Identification No. (Company's tax identification number)
Key Players & Entities
- Galecto, Inc. (company) — Registrant
- August 29, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Boston, MA (location) — Address of principal executive offices
- 2834 (sic_code) — Standard Industrial Classification for Pharmaceutical Preparations
FAQ
What specific amendments were made to Galecto, Inc.'s articles of incorporation or bylaws?
The filing indicates that amendments were made, but the specific details of these amendments are not provided in the summary text.
What is the purpose of filing a Form 8-K on August 29, 2024?
The Form 8-K was filed to report amendments to the company's articles of incorporation or bylaws and to provide financial statements and exhibits.
Where are Galecto, Inc.'s principal executive offices located?
Galecto, Inc.'s principal executive offices are located at 75 State Street, Suite 100, Boston, MA 02109.
What industry does Galecto, Inc. operate in?
Galecto, Inc. operates in the Pharmaceutical Preparations industry, as indicated by its Standard Industrial Classification code 2834.
Is this filing related to a significant event or change for Galecto, Inc. beyond routine reporting?
Based on the provided text, the filing appears to be for routine corporate reporting, including bylaw amendments and financial statements, rather than a major event.
Filing Stats: 760 words · 3 min read · ~3 pages · Grade level 10.7 · Accepted 2024-09-05 16:00:08
Key Financial Figures
- $0.00001 — e on which registered Common Stock, $0.00001 par value per share GLTO The Nasdaq
Filing Documents
- glto-20240829.htm (8-K) — 60KB
- glto-ex3_1.htm (EX-3.1) — 11KB
- 0000950170-24-103957.txt ( ) — 220KB
- glto-20240829.xsd (EX-101.SCH) — 48KB
- glto-20240829_htm.xml (XML) — 5KB
03 – Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.03 – Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. At the Annual Meeting of Stockholders (the "Special Meeting") of Galecto, Inc. (the "Company") held on June 20, 2024, the Company's stockholders approved a proposal authorizing an amendment (the "Certificate of Amendment") to the Company's Amended and Restated Certificate of Incorporation, as amended, to effect a one-time reverse stock split of the Company's outstanding shares of common stock, par value $0.00001 per share, at a ratio of not less than 1-for-4 and not greater than 1-for-25. On August 29, 2023, the Company filed with the Secretary of State of the State of Delaware the Certificate of Amendment to effect a one-time reverse stock split of the Company's common stock, at a ratio of 1-for-25 (the "Reverse Stock Split"). The Reverse Stock Split was effective at 5:00 p.m. Eastern Time, after the close of trading on The Nasdaq Capital Market, on August 29, 2024 (the "Effective Time"). At the Effective Time, every 25 shares of the Company's issued and outstanding common stock were automatically converted into one share of common stock, without any change in the par value per share. In addition, proportionate adjustments will be made to the per share exercise price and the number of shares issuable upon the exercise of all outstanding stock options and to the number of shares issued and issuable under the Company's stock incentive plans. Any stockholder who would otherwise be entitled to a fractional share of common stock created as a result of the Reverse Stock Split will be entitled to rounding up of the fractional share to the nearest whole number. Following the Reverse Stock Split, the shares of common stock will continue to trade on The Nasdaq Capital Market under the symbol "GLTO." The new CUSIP number for the common stock following the Reverse Stock Split will be 36322Q 206. The summary of the Certificate of Amendment contained herein does not purport to be comple
01 – Financial Statements and Exhibits
Item 9.01 – Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 3.1 Certificate of Amendment to Amended and Restated Certificate of Incorporation. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Galecto, Inc. Date: September 5, 2024 By: /s/ Hans T. Schambye Hans T. Schambye, M.D., Ph.D. President and Chief Executive Officer